Oncotarget: A comprehensive analysis of clinical trials in pancreatic cancer

(Impact Journals LLC) The cover for issue 38 of Oncotarget features Figure 3, 'Summary of the time and cost for drug development (modified from DiMasi et al [2016],' by Katayama, et al. which reported that Pancreatic cancer is the most aggressive common cancer and is desperately in need of novel therapies.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news